


PHARMACEUTICAL 2022

CALITHERA

Calithera Biosciences Inc. Rank 461 of 475







PHARMACEUTICAL 2022



Calithera Biosciences Inc. Rank 461 of 475

The relative strengths and weaknesses of Calithera Biosciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Calithera Biosciences Inc. compared to the market average is the variable Selling, General and Administrative Expense, increasing the Economic Capital Ratio by 66% points. The greatest weakness of Calithera Biosciences Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 585% points.

The company's Economic Capital Ratio, given in the ranking table, is -1,028%, being 751% points below the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	61,452
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	14,006
Liabilities, Non-Current	1,666
Other Assets	2,748
Other Compr. Net Income	-3.0
Other Expenses	50,875
Other Liabilities	0
Other Net Income	0
Property and Equipment	556
Research and Development	53,455
Revenues	10,095
Selling, General and Administrative Expense	20,853

Output Variable	Value in 1000 USD
Assets	64,756
Liabilities	15,672
Expenses	125,183
Stockholders Equity	49,084
Net Income	-115,088
Comprehensive Net Income	-115,090
Economic Capital Ratio	-1,028%

